Axon Enterprise, Inc $AXON Stake Boosted by Freestone Capital Holdings LLC

Freestone Capital Holdings LLC lifted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 7.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,136 shares of the biotechnology company’s stock after purchasing an additional 220 shares during the quarter. Freestone Capital Holdings LLC’s holdings in Axon Enterprise were worth $2,596,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AXON. TCTC Holdings LLC lifted its stake in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 24 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Axon Enterprise in the 1st quarter worth about $31,000. Flaharty Asset Management LLC acquired a new stake in shares of Axon Enterprise in the 1st quarter worth about $33,000. Hemington Wealth Management lifted its position in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 17 shares during the last quarter. Finally, Whipplewood Advisors LLC boosted its stake in Axon Enterprise by 192.9% during the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Price Performance

NASDAQ AXON opened at $724.10 on Tuesday. Axon Enterprise, Inc has a 12 month low of $424.99 and a 12 month high of $885.91. The firm has a market capitalization of $56.84 billion, a PE ratio of 178.79, a P/E/G ratio of 29.49 and a beta of 1.41. The company’s 50 day simple moving average is $730.27 and its 200 day simple moving average is $735.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same period in the prior year, the firm posted $1.20 earnings per share. The firm’s revenue for the quarter was up 32.6% compared to the same quarter last year. As a group, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 100 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the completion of the sale, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 59,932 shares of company stock worth $45,115,616. 4.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of several recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. UBS Group restated a “neutral” rating and issued a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Raymond James Financial reaffirmed an “outperform” rating and set a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.